ProBioGen Expands Protein And Viral Vector Production At Berlin Site, Driving Growth

ProBioGen has increased its protein and virus production facilities in its Berlin-based facility. The company has announced a new 1000L GMP production line for proteins & has also set up a new viral manufacturing building. 

"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs.", commented Dr Alfred Merz, Chief Executive Officer at ProBioGen.

These expansions will enable ProBioGen to accommodate increased production of proteins to drive biological growth and serve its partners throughout the cell line development and commercial manufacturing process. ProBioGen continues to build its position as an industry partner through its CHO.RiGHT® system and technology tools such as the company’s DirectedLuck® and GlymaxX®.

ProBioGen is bringing further innovative solutions in viral vector manufacturing based on its experience. This is because they provide cell line development for lentiviral (LV) and adeno-associated virus (AAV) generation that can create next-generation therapies with precision.